Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK-2019 in EBV-positive Nasopharyngeal Cancer
NCT03682055Phase 2Terminated
- Sponsor
- Cullinan Therapeutics
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of VK-2019 in nasopharyngeal carcinoma (NPC) (4 arms), sponsored by Cullinan Therapeutics. Primary endpoints: Adverse Events at 24 months and Dose Limiting Toxicities at 24 months. Started Apr 2019; status: terminated.
02
Drugs
VK-2019
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03682055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682055.